Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer
Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer
复制标题
DOI：
10.1016/j.clgc.2011.05.008
复制
发表时间：
2011-09-01
影响因子：
3.2
通讯作者：
Ward, David C.
中科院分区：
文献类型：
--
作者：
Gonzales, Jason C.;Fink, Louis M.;Ward, David C.
我们的目的是确定循环微小RNA miR-141作为前列腺癌(CAP)患者治疗反应的潜在生物标志物的实用性。比较21例CAP患者血浆miR-141与前列腺特异性抗原(PSA)、循环肿瘤细胞(CTC)和乳酸脱氢酶(LDH)水平的关系。数据表明miR-141值与临床病程有很强的相关性。对于前列腺癌(CAP)，前列腺特异性抗原(PSA)的测量和放射学研究不能充分预测治疗反应和生存，因此，需要新的相关生物标志物。我们和其他研究人员已经证明，PSA、循环肿瘤细胞(CTC)和乳酸脱氢酶(LDH)的纵向测量可能有助于预测治疗反应。最近的研究结果表明，在CAP患者的血浆中检测到循环microRNA(MiRNA)miR-141。因此，我们比较了21例CAP患者miR-141与CTC、LDH和PSA水平的时间变化，并对这些标记物单独或联合进行纵向检查，以确定miR-141在预测患者的临床病程和治疗反应中的作用。采用定量逆转录聚合酶链式反应检测21例CAP患者血浆miR-141水平。总共评估了35个间隔时间。PSA、CTC和miR-141的方向性变化(增加或减少)对预测临床结果(进展与无进展)的敏感性为78.9%。临床进展概率的Logistic回归模型表明，miR-141水平预测临床结果的优势比至少为8.3。MIR-141与PSA时间变化的相关性最高，相关系数R=0.77(P&t；.001)。在这项回顾性研究中，miR-141与其他临床验证的生物标记物相比，显示出类似的预测临床进展的能力。此外，miR-141与其他生物标志物的变化高度相关。
Our aim was to determine the utility of circulating micro RNA miR-141 as a potential biomarker of therapeutic response in prostate cancer (CaP) patients. We compared the values of miR-141 in plasma of 21 CaP patients to the levels of prostate specific antigen (PSA), circulating tumor cells (CTC) and lactate dehydrogenase (LDH). Data suggest a strong correlation of miR-141 values and clinical course.For prostate cancer (CaP), the measurement of prostate-specific antigen (PSA) and radiographic studies do not adequately predict response to therapy and survival, and, therefore, new relevant biomarkers are needed. We and other researchers have shown that longitudinal measurements of PSA, circulating tumor cells (CTC), and lactate dehydrogenase (LDH) may aid in predicting response to therapy. Results of recent studies have determined that circulating microRNA (miRNA) miR-141 is detected in plasma of patients with CaP. We, therefore, compared the temporal changes of miR-141 with the levels of CTC, LDH, and PSA in 21 patients with CaP, and longitudinally examined these markers alone or in combinations to determine the utility of miR-141 in the predicting a patient's clinical course and response to therapy. Levels of miR-141 in plasma of 21 patients with CaP were measured by using quantitative reverse transcription-polymerase chain reaction. A total of 35 intervals were assessed. Directional changes (increasing or decreasing) in PSA, CTC, and miR-141 had sensitivity in predicting clinical outcome (progression vs. nonprogressing) of 78.9%. Logistic regression modeling of the probability of clinical progression demonstrates that miR-141 levels predicted clinical outcomes with an odds ratio of at least 8.3. miR-141 also had the highest correlation with temporal changes of PSA with a correlation of R = 0.77 (P < .001). In this retrospective study, miR-141 demonstrated a similar ability to predict clinical progression when compared with other clinically validated biomarkers. Furthermore, miR-141 demonstrated high correlation with changes of the other biomarkers.